3M DDS Signs Licensing Agreement With Spirig Pharma AG
3M Drug Delivery Systems recently announced it has signed an exclusive licensing agreement with Spirig Pharma AG, a Swiss manufacturer of dermatological and dermocosmetic products. Spirig Pharma AG will utilize one of 3M’s immune response modifier (IRM) molecules to further its development of treatment for sun damaged skin. Spirig is known internationally for brands like its Daylong actinica, a medical device for the prevention of certain forms of non-melanoma skin cancer in at-risk patients, and Excipial moisturizer.
“The molecule offers potential for treating patients who suffer from a variety of dermatologic conditions. 3M is very proud of the many IRMs we have been developing for a variety of uses,” said Mark Tomai, PhD, Vaccine Business Development Director for 3M Drug Delivery Systems.
In addition, 3M has IRMs available for license in the areas of cancer, asthma/allergy, and as vaccine adjuvants.
“3M is pleased to align with a leading European dermatology company to further develop our IRMs. In addition to its Swiss headquarters, Spirig’s seven subsidiary locations, mainly in the EU, give us even more international reach,” added Jim Vaughan, Vice President and General Manager of 3M Drug Delivery Systems Division.
“We are excited to expand our franchise of dermatology offerings in the prevention and treatment of sun damage-related skin conditions,” said Dr. Silvio Inderbitzin, CEO of Spirig Pharma AG. “With 3M’s IRM molecule, we can enhance our portfolio with the help of an experienced partner in drug delivery technologies.”
3M Drug Delivery Systems partners with pharmaceutical and biotech companies to develop pharmaceuticals using 3M’s inhalation or transdermal drug delivery technologies. 3M offers a full range of feasibility, development, and manufacturing capabilities combined with regulatory guidance to help bring products to market. In-house resources, including toxicology, regulatory expertise, quality assurance, operations, and marketed product support, are available for each step of the development and commercialization process.
Total Page Views: 1228
